Transcript of Analysis of the Type 2 Diabetes Therapeutics Market
- 1. Analysis of the Type 2 Diabetes Therapeutics Market Global
Market Opportunities for Differentiated Therapeutics NC67-52 July
2013
- 2. 2NC67-52 This research service examines the global market
for type 2 diabetes therapeutics. Topics covered include the
following: Market definitions including segmentation and clinical
diagnostic criteria Important trends, unmet needs, opportunities
and risks in the management of type 2 diabetes Spotlight on
companies and pipeline products to watch Comprehensive product and
pipeline synopses and analyses Comparative product profile and
clinical efficacy analyses Launch timelines and patent expirations
Cardiovascular outcomes trials timeline Segment-level forecasts and
discussions of insulin and non-insulin therapeutics Regional
forecasts and discussions including evaluation of the United
States, major European markets, and select Asia-Pacific markets
Contents Source: Frost & Sullivan
- 3. 3NC67-52 The information contained in this research service
was derived from a variety of relevant primary and secondary
information sources. Primary interviews were conducted with
industry participants in positions such as chairman and CEO,
director of investor relations, director of business development,
chief business officer, media relations, and international key
opinion leaders (KOL). Secondary data sources include disease and
public health organization websites [International Diabetes
federation (IDF), World Health Organization (WHO), American
Diabetes Association (ADA)]; company publications (annual reports,
U.S. Securities and Exchange Commission (SEC) filings, investor
presentations, earnings transcripts, and press releases);
government public sources; pharmaceutical industry databases; and
published articles in scientific and medical journals. For the
United States, revenue forecasting is performed using a robust,
data-driven, bottom-up, patient-based approach. Marketed drugs and
potential new entrants in Phase 3 of development and beyond are
individually forecast, and aggregate figures are provided. For
other regions, forecasting is performed using a top-down model.
Methodology Source: Frost & Sullivan
- 4. 4NC67-52 Scope and Segmentation Source: Frost & Sullivan
Geographic coverage Global Study period 20092017 Base year 2012
Forecast period 20132017 Monetary unit US Dollars This research
service evaluates the global market for type 2 diabetes
therapeutics. It does not evaluate other diabetes care markets such
as glucose meters and supplies, insulin syringes, insulin pumps, or
glucose tablets and other nutritionals. Included are insulin and
insulin analogues, oral anti-diabetic drugs (OAD) and injectable
anti-diabetic drugs apart form insulin. In-depth analysis is
provided for the major markets of the United States and Europe. The
emerging markets of China, South Korea, Malaysia, Indonesia,
Vietnam, and India are also evaluated with an emphasis on the
regional environment. Units are patients. Treated patient numbers,
when estimated, are derived from annual sales revenue and annual
cost of therapy. The price is the annual cost of therapy. Average
annual cost of therapy is based on the average wholesale price
(AWP) per drug, as reported in Thomson Reuters Red Book. Hospital
or clinic- associated expenses are not included in the cost of
therapy. Indication-specific annual revenue as reported is used
when available; otherwise, estimates are used.
- 5. 5NC67-52 Key Questions This Study Will Answer Source: Frost
& Sullivan Is the market growing, how long will it continue to
grow, and at what rate? Which segments and geographic regions are
experiencing the fastest growth? How will the competitive landscape
be affected by new product launches and patent expiries? How do the
product profiles of new products compare to existing products? What
are the remaining unmet needs of diabetes patients? How can
participants and emerging competitors meet these needs? What are
the major trends affecting the growth of this market? What are the
biggest risks for participants or potential participants? What are
the biggest opportunities and risks in emerging markets? What is
the relative impact of social, economic, pricing constraints, and
regulatory factors on emerging market penetration? How competitive
is this market? Is this market trending toward increasing or
decreasing competitiveness?
- 6. 6NC67-52 Insulins Total Type 2 Diabetes Therapeutics Market
Total Type 2 Diabetes Therapeutics Market: Market Segmentation,
Global, 2012 Non-Insulin Therapeutics Rapid insulin Add-on to SOC
Premix/ Intermediate insulin Market Segmentation Source: Frost
& Sullivan Standard of Care (SOC) Basal insulin Biguinides
Sulfonylureas Meglitinides Glitazones Incretins SGLT2s* Human
Insulin Modern Insulins *Sodium-glucose co-transporter 2 Regular
insulin Premix/ Intermediate insulin
- 7. 7NC67-52 New Market Opportunities Source: Frost &
Sullivan Unmet Needs The most important unmet need of diabetes
patients remains clinically meaningful cardiovascular benefit.
Although improvements in surrogate markers such as lipids and
inflammatory biomarkers are a step in the right direction, clear
demonstration of reduced risk of a cardiovascular event is critical
for evidence-based medicine. Although many newer therapies are able
to more effectively manage blood glucose levels, impact on disease
progression is still lacking, and most patients must still progress
through an increasingly complicated therapeutic regimen, usually
culminating at insulin therapy. The population with prediabetes is
estimated to be approximately three times the size of the diabetes
population. Prophylactic therapy based on identified precursors to
full blown diabetes is a key unmet need. Current Participant
Strategies Novo Nordisk: Meets the diverse needs of insulin
patients by providing a complete insulin portfolio. Also invests in
other biopharma antidiabetics such as Victoza. Novo Nordisk focuses
on the highly lucrative biopharma sector where they have
considerable capability and barriers to entry are higher. Merck:
Achieved market leadership among non-insulin antidiabetics with a
single first-in- class blockbuster, Januvia. Januvia was the first
add-on oral drug with no weight gain or other troublesome side
effects, allowing it to rapidly capture a large market share by
addressing a key unmet need of patients. Sanofi: Similar to Merck,
Sanofi has achieved the number two spot in the entire diabetes
therapeutics market with the success of their blockbuster insulin
Lantus. Lantus was the first long-acting basal insulin, greatly
increasing the convenience of insulin therapy.
- 8. 8NC67-52 Rapid Basal Parenteral Oral/transmucosal/inhaled
Pre-Mix/Intermediate Total Type 2 Diabetes Therapeutics Market:
Competitive LandscapeInsulin Segment, Marketed and Pipeline
Products by Type, Global, 2012 Competitive LandscapeInsulin Segment
Marketed and Pipeline Products (continued) Source: Frost &
Sullivan Phase 1 Phase 3 MarketPreregistrationPhase 2 Tresiba (EU,
JP) (NVO) Tresiba (US) (NVO) NN1954 (NVO) Levemir (NVO) Lantus
(SNY) LY2605541 (BING/LLY) NN1953 (NVO) SuliXen (Xenetic
Biosciences) LAI287 (NN1436) (NVO) Nodlin (NOD Pharmaceuticals)
LY2963016 (BING/LLY) IDegLira (NVO) HOE901/AVE0010 (SNY/Zealand)
Humalog (LLY) Novolog (NVO) Apidra (SNY) BIOD-238 (Biodel) Novolog
Mix 75/25 (NVO) Humalog 50/50 (LLY) Humalog25/75 (LLY) Humulin N
(LLY) BIOD-123 (Biodel) Ryzodeg (EU, JP) (NVO) Ryzodeg (US) (NVO)
ORMD-0801 (Oramed) Afrezza (Mannkind) BIOD-250 (Biodel) NN1218 (NVO
Oral-lyn (Generex) IN-105 (Biocon/BMY) Insuman (SNY) Humulin R
(LLY) HM12460A (LAPS-Insulin) (Hanmi Pharmaceutical) Insulin
glargine U-300 (SNY)
- 9. 9NC67-52 Pipeline AnalysisInsulin Segment Products in Late
Stage Clinical Development Product Company MOA/Class Phase Dosing/
Administration Comments Afrezza Mannkind, Emisphere Technologies
Rapid-acting insulin analogue Phase 3 Inhalation Potential
first-in-class inhalable insulin IDegLira (insulin degludec +
liraglutide) Novo Nordisk Basal insulin + GLP-1 analogue fixed
combination Phase 3 SC injection once daily Complimentary
combination; potential superior efficacy among all anti-diabetics
Insulin glargine U- 300 Sanofi Basal insulin Phase 3 SC injection
once daily Concentrated formulation with improved PK/PD LY2605541
(insulin peglispro) Eli Lilly Basal insulin analogue Phase 3 SC
injection once daily Liver-targeted; potential for improved
outcomes, particularly for liver-specific insulin resistance
LY2963016 (insulin glargine) Boehringer Ingelheim/Eli Lilly Basal
insulin analogue Phase 3 SC injection once daily Biosimilar Lantus
Oral-lyn Generex Rapid-acting insulin analogue Phase 3 Transmucosal
(buccal spray) Needle-less administration, but multiple sprays per
dose required; possible absorption issues Source: Frost &
Sullivan Total Type 2 Diabetes Therapeutics Market: Insulin
Segment, Late Stage Product Synopsis, Global, 2012
- 10. 10NC67-52 Pipeline AnalysisInsulin Segment Products in
Midstage Clinical Development Product Company MOA/Class Phase
Dosing/ Administration Comments BIOD-123 Biodel Ultra-rapid-acting
recombinant human insulin formulation Phase 2 SC injection
Absorption 64% faster than Humalog; improved injection site
reaction profile compared to first generation formulation (Linjeta)
FIAsp/NN1218 Novo Nordisk Ultra-rapid acting insulin aspart Phase 1
(Phase 3 ready) SC injection Achieved proof-of-concept in type 1
and type 2 diabetes; Three Phase 3 trials to be initiated Q3-2013
HOE901/AVE0010 FC (Lantus + Lyxumia ) Sanofi, Zealand Basal insulin
+ GLP-1 analogue fixed combination Phase 2 SC injection once daily
Complimentary combination; injection device in development that
allows for adjustment of insulin dose with a fixed lixisenatide
dose IN-105 Biocon, Bristol-Myers Squibb Prandial insulin conjugate
Phase 2 Oral (single tablet) Liver-targeted ORMD-0801 Oramed Basal
insulin Phase 2 Oral (2 pills/day) Oral GLP-1 also in development;
potential for insulin + GLP-1 FDC pill Source: Frost & Sullivan
Total Type 2 Diabetes Therapeutics Market: Insulin Segment,
Midstage Product Synopsis, Global, 2012
- 11. 11NC67-52 Pipeline AnalysisInsulin Segment Products in
Early Stage Clinical Development Product Company MOA/Class Phase
Dosing/ Administration Comments BIOD-238 Biodel Ultra-rapid-acting
insulin analogue (Humalog-based) Phase 1 SC injection Reduced EDTA
and no MgSO4 BIOD-250 Biodel Ultra-rapid-acting insulin analogue
Phase 1 SC injection MgSO4 added HM12460A (LAPS-Insulin) Hanmi
Pharmaceutical Ultra-long-acting insulin Phase 1 SC injection, once
weekly Preclinical evidence of comparable glucose lowering versus
daily basal insulins NN1436/LAI287 Novo Nordisk Basal insulin
analogue Phase 1 SC injection, once weekly Phase 1 trial in type 1
diabetes patients underway NN1953/OI338GT Novo Nordisk, Merrion
Pharmaceuticals Basal insulin analogue Phase 1 Oral (tablet)
Multiple dose Phase 1 trial underway; developed using Merrions
Gastrointestinal Permeation Enhancement Technology (GIPET) Source:
Frost & Sullivan Total Type 2 Diabetes Therapeutics Market:
Insulin Segment, Early Stage Product Synopsis, Global, 2012
- 12. 12NC67-52 Pipeline AnalysisInsulin Segment Products in
Early Stage Clinical Development (continued) Product Company
MOA/Class Phase Dosing/ Administration Comments NN1954/OI362GT Novo
Nordisk, Merrion Pharmaceuticals Basal insulin analogue Phase 1
Oral (tablet) Single dose Phase 1 study completed; developed using
Merrions GIPET technology Nodlin NOD Pharmaceuticals Basal insulin
Phase 1 (China) Oral Technology encapsulates macromolecules into
bio- adhesive nano-particles SuliXen Xenetic Biosciences Basal
insulin analogue Phase 1 SC injection Potentially less immunogenic
BIOD-530 Biodel Ultra-rapid-acting concentrated insulin Preclinical
SC injection or pump; U-400 Potential to be the only concentrated
insulin for pump use Source: Frost & Sullivan
- 13. 13NC67-52 Parenteral Oral Generics are not included.
Source: Frost & Sullivan Total Type 2 Diabetes Therapeutics
Market: Competitive LandscapeNonInsulin Segment, Late Stage and
Marketed Products by Drug Class, Global, 2012 Competitive
LandscapeNonInsulin Segment Late Stage and Marketed Products
TZD/PPAR DPP-4 GLP-1 FDC Miglitinide Other* SGLT2 Januvia (MRK)
Nesina (Takeda/ Furiea) Onglyza (BMY/AZN) Galvus (NVS) Tradjenta
(BING/LLY) Zemiglo (LG Life Sciences) Tenelia (Mitsubishi
Tanabe/Daiichi Sankyo) Kazano (Takeda/Furiex) Avandamet (GSK)
Janumet / Janumet XR (MRK) Kombiglyze (BMY/AZN) Avandaryl/Avaglim
(GSK) Oseni/Liovel (Takeda) Actoplus Met/Actoplus Met XR/Competact
XR (Takeda) Juvisync (MRK) Duetact (Takeda) Jentadueto (BING/LLY)
Eucreas/GalvusMet (Novartis) Forxiga (EU) (BMY/AZN)
Prandin/NovoNorm (NVO) Starlix (Novartis) Glufast Kissei
Pharmaceutical Cycloset (Santarus) Symlin (BMY/AZN) Avandia (GSK)
Actos (Takeda) Bydureon (BMY) Victoza (NVO) Lyxumia (SNY) Byetta
(BMY) Pre-registration Phase 3 Market Tandemact+alogliptin (Takeda)
Forxiga + MET (BMY/AZN) Empagliflozin + linagliptin (BING/LLY)
Glimepiride + atorvastatin (GSK) Canagliflozin/MET (US) (JNJ)
Dulaglutide (LLY) Albiglutide (EU) (GSK)Canagliflozin/MET (EU)
(JNJ) Empagliflozin + MET (BING/LLY) IDegLira (NVO) Tradjenta + PIO
(BING/LLY) Gemigliptin + MET (LG Life Sciences) ITCA 650 (Intarcia
Therapeutics) Trelagliptin (JP) (Takeda/Furiex) MK-3102 (MRK)
Semaglutide (NVO)Empagliflozin (BING/LLY) Aleglitazar (Roche)
Albiglutide (US) (GSK) TAK-875 (Takeda) Ipragliflozin
(Astellas/Kotobuki Pharmaceutical) Luseogliflozin (Taisho/NVS)
Invokana (EU) (JNJ) Tofogliflozin (Chugai/Kowa/SNY) Invokana (US)
(JNJ) Forxiga (US) (BMY/AZN) * Classes other than those listed or
undisclosed
- 14. 14NC67-52 Marketed Product SynopsisNoninsulin Segment Addon
Products Product Company MOA/Class First Launch Markets US Patent
Expiry Actos (pioglitazone) Takeda TZD 1999 Worldwide Expired
Actoplus Met (pioglitazone/ metformin IR) Takeda FDC (TZD + MET)
2005 Worldwide Expired Actoplus Met XR/ Competact XR (pioglitazone/
metformin XR) Takeda, Watson FDC (TZD + MET) 2010 Worldwide 2026
Avandia (rosiglitazone) GlaxoSmithKline TZD 1999 Worldwide Expired
Avandamet (rosiglitazone/ metformin IR) GlaxoSmithKline FDC (TZD +
MET) 2002 Worldwide Expired Avandaryl/Avaglim (rosiglitazone/
glimepiride) GlaxoSmithKline, Sanofi FDC (TZD + SU) 2006 Worldwide
Expired Bydureon (exenatide XR) Bristol-Myers Squibb/Eli Lilly
GLP-1 2011 Worldwide 2025 Source: Frost & Sullivan Total Type 2
Diabetes Therapeutics Market: Non-insulin Segment, Add-on Marketed
Product Synopsis, Global, 2012
- 15. 15NC67-52 Marketed Product SynopsisNoninsulin Segment Addon
Products (continued) Product Company MOA/Class First Launch Markets
US Patent Expiry Byetta (exenatide) Bristol-Myers Squibb GLP-1 2005
Worldwide 2017 Cycloset (bromocriptine mesylate) Santarus Other
(dopamine receptor agonist) 2010 Worldwide 2015 Duetact
(pioglitazone/ glimepiride) Takeda FDC (TZD + SU) 2006 Worldwide
Expired Eucreas/GalvusMet (vildagliptin/ metformin) Novartis FDC
(DPP-4 + MET) 2007 Worldwide ex-US Unknown Forxiga (dapagliflozin)
Bristol-Myers Squibb, AstraZeneca SGLT2 2012 Europe (US approval
pending) 2020 Galvus (vildagliptin) Novartis DPP-4 2007 Worldwide
ex-US Unknown Glufast (mitiglinide) Kissei Pharmaceutical
Meglitinide APAC Unknown Invokana (canagliflozin) Johnson &
Johnson SGLT2 2013 US (EU approval pending) 2024 Source: Frost
& Sullivan
- 16. 16NC67-52 Product Company MOA/Class First Launch Markets US
Patent Expiry Janumet XR (sitagliptin + metformin XR) Merck,
Depomed FDC (DPP-4 + MET) 2012 Worldwide 2022 Janumet
(sitagliptin/metformin) Merck FDC (DPP-4 + MET) 2007 Worldwide 2022
Januvia (sitagliptin) Merck DPP-4 2006 Worldwide 2022 Jentadueto
(linagliptin/metformin) Boehringer Ingelheim/Eli Lilly FDC (DPP-4 +
MET) 2012 Worldwide 2025 Juvisync (sitagliptin/ simvastatin) Merck
FDC (DPP-4 + statin) 2009 (JP) 2011 (US) Worldwide 2026 Kazano
(alogliptin/metformin) Takeda FDC (DPP-4 + MET) 2013 US 2016
Kombiglyze XR (saxagliptin/metformin XR) Bristol-Myers Squibb/
AstraZeneca FDC (DPP-4 + MET) 2011 Worldwide 2023 Lyxumia
(lixisenatide) Sanofi GLP-1 2013 Europe (US approval pending) 2020
Nesina (alogliptin) Takeda DPP-4 2010 Japan, US 2016 Source: Frost
& Sullivan Marketed Product SynopsisNoninsulin Segment Addon
Products (continued)
- 17. 17NC67-52 Product Company MOA/Class First Launch Markets US
Patent Expiry Onglyza (saxagliptin) Bristol-Myers Squibb/
AstraZeneca DPP-4 2009 Worldwide 2021 Oseni/Liovel (alogliptin/
pioglitazone) Takeda FDC (DPP-4 + TZD) 2011 Japan, US 2016
Prandin/NovoNorm (repaglinide) Novo Nordisk Meglitinide 1998 US,
Europe Expired Starlix (neteglinide) Novartis Meglitinide 2000
Worldwide Expired Symlin (pramlintide acetate) Bristol-Myers
Squibb, AstraZeneca Other (amylin receptor antagonist) 2005
Worldwide 2019 Tenelia (Teneligliptin/MP-513) Mitsubishi Tanabe
DPP-4 2012 Japan Unknown Tradjenta (linagliptin) Boehringer
Ingelheim/Eli Lilly DPP-4 2011 Worldwide 2025 Victoza (liraglutide)
Novo Nordisk GLP-1 2009 Worldwide 2022 Zemiglo (gemigliptin) LG
Life Sciences DPP-4 2012 Turkey, Korea, China Unknown Source: Frost
& Sullivan Marketed Product SynopsisNoninsulin Segment Addon
Products (continued)
- 18. 18NC67-52 Timeline of Product Launches
2018201720162015201420132010 2011 2012 Japan launchEU launch Total
Type 2 Diabetes Therapeutics Market: Timeline of Product Launches,
Global, 20102018 The base year is 2012. Source: Frost &
Sullivan Key Takeaway: The diabetes market will see a steady stream
of new product launches over the next six years. FIAsp Affrezza
IDegLira Semaglutide Aleglitazar Empagliflozin Dulaglutide
Albiglutide ITCA 650 Invokana MK-3102TAK-875 LyxumiaLyxumia
Bydureon Janumet XRTradjenta Jentadueto Juvisync Nesina Nesina
Kazano Oseni Forxiga Note: Product launches after mid-2013 are
estimated based on regulatory filing dates and/or publically
communicated estimates US launch First Global Launch First Global
Launch Invokana Invokana Empagliflozin Bydureon Bydureon Nesina
Forxiga Forxiga Tradjenta Tradjenta Lyxumia Albiglutide
- 19. 19NC67-52 2005 2010 2015 2020 20252000 2030 Patent
Expirations Total Type 2 Diabetes Therapeutics Market: Patent
Expirations, Insulin Segment, Global, 20002030 Source: Frost &
SullivanYear Patent Expirations Insulin SegmentProduct Humulin 2000
Humalog 2013 Novolog/NovoRapid 2014 Lantus 2015 Afrezza 2020 Apidra
2023 Levemir 2019 Insulin/insulin analogue
- 20. 20NC67-52 2005 2010 2015 2020 20252000 2030 Patent
Expirations Total Type 2 Diabetes Therapeutics Market: Patent
Expirations, Non-insulin Segment, Global, 20002030 Source: Frost
& Sullivan Year Patent Expirations Noninsulin Segment * Market
exclusivity to 2018 Product Other classTZD GLP-1 DPP-4 SGLT2 Amaryl
2005 Glucophage XR 2003 Glucotrol XL 2003 Glucobay 2007 Nesina
2016* Cycloset 2015 Starlix 2009 Avandia 2012 Prandin 2011 Actos
2011 Glumetza 2016 Juvisync 2026 Forxiga 2020 Galvus 2020 Symlin
2019 Fortamet 2018 Byetta 2017 Victoza 2022 Januvia 2022 Onglyza
2021 Lyxumia 2020 Jentadueto 2025 Tradjenta 2025 Bydureon 2025
Invokana 2024 Kombiglyze XR 2023 Actoplus Met XR 2026
- 21. 21NC67-52 CardiovascularOutcomesTrial 2015 20202005 Patent
Expirations Total Type 2 Diabetes Therapeutics Market:
Cardiovascular Outcomes Trials Timeline, Global, 2012 Source:
Clinicaltrials.gov and Frost & Sullivan analysisYear
Cardiovascular Outcomes Trials Timeline 2010 TECOS (N =
14,000)Sitagliptin EXAMINE (N = 5,400)Alogliptin CANVAS (N =
4,330)Canaglifozin EXSCEL (N = 9,500)Exenatide ELIXA (N =
6,000)Lixisenatide N = 7,000Empagliflozin REWIND (N =
9,622)Dulaglutide (N = 5,000)TAK-875 MK-3102-018 AM5 (N =
4,000)MK-3102 AleCardio (N = 19,000)Aleglitazar SUSTAIN (N =
3,260)Semaglutide (N = 2,000)ITCA 650 DECLARE (N =
17,150)Dapagliflozin CAROLINA N = 6,000Linagliptin LEADER N =
9,340Liraglutide SAVOR (N = 16,500)Saxagliptin ORIGIN (N = 12,537)
Insulin glargine
- 22. 22NC67-52 Comparative Product Profiles of Promising
Late-stage Candidates Source: Frost & Sullivan Drug (Company)
Advantages Disadvantages IDegLira (Novo Nordisk) Superior efficacy
versus all known antidiabetics Physician acceptance of the
insulin/GLP- 1 combination Regulatory delay ITCA 650 (Intarcia
Therapeutics) Convenience of once yearly implantation Physician
familiarity with mechanism Inconvenience of removal if immediately
necessary Forxiga (Bristol-Myers Squibb/AstraZeneca) and Invokana
(Johnson & Johnson) Weight loss and BP lowering Convenience of
once-daily oral therapy Ease of combination therapy Unknown long
term safety profile Potential for dapagliflozin cancer signal to be
class effect Genitourinary side effects Contraindicated in certain
patient types (renal insufficiency) LY2605541 (Eli Lilly)
Liver-targeted action Improved efficacy in liver-insulin resistance
Weight loss Unknown long term safety/efficacy profile Total Type 2
Diabetes Therapeutics Market: Comparative Product Profiles of
Promising Late-stage Candidates, Global, 2012
- 23. 23NC67-52 Please find the detailed Table of Contents for
Analysis of the Type 2 Diabetes Therapeutics Market: Global Market
Opportunities for Differentiated Therapeutics beginning on slide
25. Additional sources of information on diabetes: European
Diabetes Diagnostics Market Indian Diabetes Market European
Diabetes Therapeutics Market 2010 U.S. Type 2 Diabetes Patients'
Choice: Awareness, Usage, and Preferences of Injection Pens
Additional Frost & Sullivan offerings: Talk to an analyst Take
our DNA Survey Arrange a Growth Workshop Explore the Growth
Excellence Matrix 2.0 Attend a relevant live or virtual event
Explore Healthcare Growth Consulting opportunities Learn More Next
Steps Source: Frost & Sullivan
- 24. 24NC67-52 For More Information Jennifer Carson Corporate
Communications (+1) 210.247.2450 jennifer.carson@frost.com
- 25. 25NC67-52 Contents Section Slide Number Executive Summary
39 Key Findings 40 Scope and Segmentation 42 Key Questions This
Study Will Answer 43 Market Engineering Measurements 44 CEOs
Perspective 46 Key Companies to Watch 47 Executive Summary3 Big
Predictions 48 Market Overview 49 Market Background 50 Market
Segmentation 52 Market Segmentation Discussion 53 Global Market
Perspective 56 Defining Healthcare Trends in the Future 57
- 26. 26NC67-52 Contents (continued) Section Slide Number
Competitive Playbook 58 New Market Opportunities 59 Merger,
Acquisition, and Partnership Assessment 61 Driver, Restraints, and
TrendsTotal Market 62 Market Drivers 63 Market Restraints 64
Forecasts and TrendsTotal Market 65 Market Engineering Measurements
66 Forecast Assumptions and Definitions 68 Revenue Forecast 69
Revenue Forecast Discussion 70 Percent Revenue Forecast by Region
72 Revenue Forecast by Region 73
- 27. 27NC67-52 Contents (continued) Section Slide Number
Competitive Environment 74 Competitive LandscapeInsulin Segment:
Marketed and Pipeline Products 75 Marketed Product SynopsisInsulin
Segment 77 Marketed Product ProfilesInsulin Segment: Rapid-acting
Insulin 79 Marketed Product ProfilesInsulin Segment:
Intermediate-acting/Premix Insulin 80 Marketed Product
ProfilesInsulin Segment: Basal Insulin 81 Pipeline AnalysisInsulin
Segment: Products in Late Stage Clinical Development 82 Pipeline
AnalysisInsulin Segment: Products in Mid-stage Clinical Development
83 Pipeline AnalysisInsulin Segment: Products in Early Stage
Clinical Development 84 Competitive LandscapeNoninsulin Segment:
Count of Marketed and Pipeline Products 86 Competitive
LandscapeNonInsulin Segment: Late Stage and Marketed Products 87
Competitive LandscapeNonInsulin Segment: Early Stage Pipeline
Products 88 Marketed Product SynopsisNoninsulin Segment: First Line
Standard of Care Products 89 Marketed Product SynopsisNoninsulin
Segment: Addon Products 90
- 28. 28NC67-52 Contents (continued) Section Slide Number
Marketed Product ProfilesNon-insulin Segment: DPP-4 Class 94
Marketed Product ProfilesNon-insulin Segment: GLP-1 Class 96
Marketed Product ProfilesNon-insulin Segment: SGLT2 Class 98
Pipeline AnalysisNonInsulin Segment: Products in Late Stage
Clinical Development 99 Pipeline AnalysisNonInsulin Segment:
Products in Mid-stage Clinical Development 101 Pipeline
AnalysisNonInsulin Segment: Products in Early Stage Clinical
Development 105 Market Share Evolution 110 Market Share Analysis
111 Top Competitors 112 Timeline of Product Launches 113 Patent
Expirations: Insulin Segment 114 Patent Expirations: Noninsulin
Segment 115 Exclusivity Periods of Key Products: Insulin Segment
116
- 29. 29NC67-52 Contents (continued) Section Slide Number
Exclusivity Periods of Key Products: Noninsulin Segment 117
Cardiovascular Outcomes Trials Timeline 119 Comparative Product
Profiles of Promising Late-stage Candidates 120 Comparative
Efficacy Analysis 121 Comparative Efficacy Analysis Discussion 123
Insulin Segment Breakdown 124 Insulin Segment Key Findings 125
Market Engineering Measurements 126 Revenue Forecast 127 Revenue
Forecast Discussion 128 Noninsulin Segment Breakdown 129
Non-insulin Segment Key Findings 130 Market Engineering
Measurements 131 Revenue Forecast 132 Revenue Forecast Discussion
133
- 30. 30NC67-52 Contents (continued) Section Slide Number United
States Breakdown 134 Insulin Segment Revenue Forecast 135 Insulin
Segment Revenue Forecast by Class 136 Insulin Segment Revenue
Forecast Discussion 137 Insulin Segment Type 2 Diabetes Prevalence
and Treated Patient Forecast 138 Insulin Segment Type 2 Diabetes
Prevalence and Treated Patient Forecast Discussion 139 Non-insulin
Segment Revenue Forecast 140 Non-insulin Segment Revenue Forecast
by Class 141 Non-insulin Segment Revenue Forecast Discussion 142
Non-insulin Segment Type 2 Diabetes Prevalence and Treated Patient
Forecast 143 Non-insulin Segment Type 2 Diabetes Prevalence and
Treated Patient Forecast Discussion 144 Pricing Analysis 145 Market
Analysis 146 PESTLE Analysis 147
- 31. 31NC67-52 Contents (continued) Section Slide Number United
Kingdom Breakdown 148 The United Kingdom Diabetes Outlook 149
Insulin Segment Revenue Forecast 150 Insulin Segment Revenue
Forecast Discussion 151 Non-insulin Segment Revenue Forecast 152
Non-insulin Segment Revenue Forecast Discussion 153 Regulatory
Policy Framework 154 Pricing and Reimbursement 155 Type 2 Diabetes
Prevalence Forecast 156 Type 2 Diabetes Prevalence Forecast
Discussion 157 Market Analysis 159
- 32. 32NC67-52 Contents (continued) Section Slide Number Germany
Breakdown 160 Germany Diabetes Outlook 161 Insulin Segment Revenue
Forecast 162 Insulin Segment Revenue Forecast Discussion 163
Non-insulin Segment Revenue Forecast 164 Non-insulin Segment
Revenue Forecast Discussion 165 Regulatory Policy Framework 166
Pricing and Reimbursement 167 Type 2 Diabetes Prevalence Forecast
168 Type 2 Diabetes Prevalence Forecast Discussion 169 Market
Analysis 171
- 33. 33NC67-52 Contents (continued) Section Slide Number France
Breakdown 172 France Diabetes Outlook 173 Insulin Segment Revenue
Forecast 174 Insulin Segment Revenue Forecast Discussion 175
Non-insulin Segment Revenue Forecast 176 Non-insulin Segment
Revenue Forecast Discussion 177 Regulatory Policy Framework 178
Pricing and Reimbursement 179 Type 2 Diabetes Prevalence Forecast
180 Type 2 Diabetes Prevalence Forecast Discussion 181 Market
Analysis 183
- 34. 34NC67-52 Contents (continued) Section Slide Number Italy
Breakdown 184 Italy Diabetes Outlook 185 Insulin Segment Revenue
Forecast 186 Insulin Segment Revenue Forecast Discussion 187
Non-insulin Segment Revenue Forecast 188 Non-insulin Segment
Revenue Forecast Discussion 189 Regulatory Policy Framework 190
Pricing and Reimbursement 191 Type 2 Diabetes Prevalence Forecast
192 Type 2 Diabetes Prevalence Forecast Discussion 193 Market
Analysis 195
- 35. 35NC67-52 Contents (continued) Section Slide Number Spain
Breakdown 196 Spain Diabetes Outlook 197 Insulin Segment Revenue
Forecast 198 Insulin Segment Revenue Forecast Discussion 199
Non-insulin Segment Revenue Forecast 200 Non-insulin Segment
Revenue Forecast Discussion 201 Regulatory Policy Framework 202
Pricing and Reimbursement 203 Type 2 Diabetes Prevalence Forecast
204 Type 2 Diabetes Prevalence Forecast Discussion 205 Market
Analysis 207
- 36. 36NC67-52 Contents (continued) Section Slide Number Benelux
Breakdown 208 Benelux Diabetes Outlook 209 Insulin Segment Revenue
Forecast 210 Insulin Segment Revenue Forecast Discussion 211
Non-insulin Segment Revenue Forecast 212 Non-insulin Segment
Revenue Forecast Discussion 213 Regulatory Policy Framework 214
Pricing and Reimbursement 217 Type 2 Diabetes Prevalence Forecast
220 Type 2 Diabetes Prevalence Forecast Discussion 221 Market
Analysis 223
- 37. 37NC67-52 Contents (continued) Section Slide Number
Scandinavia Breakdown 224 Scandinavia Diabetes Outlook 225 Insulin
Segment Revenue Forecast 226 Insulin Segment Revenue Forecast
Discussion 227 Non-insulin Segment Revenue Forecast 228 Non-insulin
Segment Revenue Forecast Discussion 229 Regulatory Policy Framework
230 Pricing and Reimbursement 234 Type 2 Diabetes Prevalence
Forecast 238 Type 2 Diabetes Prevalence Forecast Discussion 239
Market Analysis 241
- 38. 38NC67-52 Contents (continued) Section Slide Number China
Breakdown 242 Market Overview 243 Insulin Segment Revenue Forecast
244 Insulin Segment Revenue Forecast Discussion 245 Non-insulin
Segment Revenue Forecast 246 Non-insulin Segment Revenue Forecast
Discussion 247 Pricing Analysis 248 Type 2 Diabetes Prevalence and
Treated Patient Forecast 249 Type 2 Diabetes Prevalence and Treated
Patient Forecast Discussion 250 Market Analysis 251
- 39. 39NC67-52 Contents (continued) Section Slide Number South
Korea Breakdown 252 South Korea Diabetes Outlook 253 Insulin
Segment Revenue Forecast 254 Insulin Segment Revenue Forecast
Discussion 255 Non-insulin Segment Revenue Forecast 256 Non-insulin
Segment Revenue Forecast Discussion 257 Pricing Analysis 258 Type 2
Diabetes Prevalence and Treated Patient Forecast 259 Type 2
Diabetes Prevalence and Treated Patient Forecast Discussion 260
Market Analysis 262
- 40. 40NC67-52 Contents (continued) Section Slide Number
Malaysia Breakdown 264 Malaysia Diabetes Outlook 265 Insulin
Segment Revenue Forecast 266 Insulin Segment Revenue Forecast
Discussion 267 Non-insulin Segment Revenue Forecast 268 Non-insulin
Segment Revenue Forecast Discussion 269 Pricing Analysis 270 Type 2
Diabetes Prevalence and Treated Patient Forecast 271 Type 2
Diabetes Prevalence and Treated Patient Forecast Discussion 272
Market Analysis 274
- 41. 41NC67-52 Contents (continued) Section Slide Number
Indonesia Breakdown 276 Indonesia Diabetes Outlook 277 Insulin
Segment Revenue Forecast 278 Insulin Segment Revenue Forecast
Discussion 279 Non-insulin Segment Revenue Forecast 280 Non-insulin
Segment Revenue Forecast Discussion 281 Pricing Analysis 282 Type 2
Diabetes Prevalence and Treated Patient Forecast 283 Type 2
Diabetes Prevalence and Treated Patient Forecast Discussion 284
Market Analysis 286
- 42. 42NC67-52 Contents (continued) Section Slide Number Vietnam
Breakdown 287 Vietnam Diabetes Outlook 288 Insulin Segment Revenue
Forecast 289 Insulin Segment Revenue Forecast Discussion 290
Non-insulin Segment Revenue Forecast 291 Non-insulin Segment
Revenue Forecast Discussion 292 Pricing Analysis 294 Type 2
Diabetes Prevalence and Treated Patient Forecast 295 Type 2
Diabetes Prevalence and Treated Patient Forecast Discussion 296
Market Analysis 298
- 43. 43NC67-52 Contents (continued) Section Slide Number India
Breakdown 299 Insulin Segment Revenue Forecast 300 Insulin Segment
Revenue Forecast Discussion 301 Non-insulin Segment Revenue
Forecast 302 Non-insulin Segment Revenue Forecast Discussion 303
Pricing Analysis 304 Type 2 Diabetes Prevalence and Treated Patient
Forecast 305 Type 2 Diabetes Prevalence and Treated Patient
Forecast Discussion 306 Market Analysis 307 Customer and End-user
Analysis 308 KOL Commentary 309 Key Companies to Watch 310
Companies to Watch 311
- 44. 44NC67-52 Contents (continued) Section Slide Number The
Last Word 316 The Last Word3 Big Predictions 317 The Last
WordDiscussion 318 Legal Disclaimer 321 Appendix 322 Drivers
Explained 323 Restraints Explained 327 Decision Support Database
331 Additional Sources of Information on Diabetes 337 Market
Engineering Methodology 338 Learn MoreNext Steps 339
- 45. 45NC67-52 List of Exhibits Exhibit Slide Number Total Type
2 Diabetes Therapeutics Market: Market Engineering Measurements,
Global, 2012 44 Total Type 2 Diabetes Therapeutics Market: Market
Segmentation, Global, 2012 52 Total Type 2 Diabetes Therapeutics
Market: Growth Rate Breakdown by Geographic Region, Global, 2012 56
Total Type 2 Diabetes Therapeutics Market: Market Outlook, Global,
2012 and 2022 57 Total Type 2 Diabetes Therapeutics Market:
Game-changing Strategies, Global, 2012 60 Total Type 2Diabetes
Therapeutics Market: Market Outlook, Global, 20072013 61 Total Type
2Diabetes Therapeutics Market: Key Market Drivers, Global, 20132017
63 Total Type 2Diabetes Therapeutics Market: Key Market Restraints,
Global, 20132017 64 Total Type 2 Diabetes Therapeutics Market:
Market Engineering Measurements, Global, 2012 66 Total Type 2
Diabetes Therapeutics Market: Revenue Forecast, Global, 20092017 69
Total Type 2 Diabetes Therapeutics Market: Major New Product
Launches, Global, 2013 2017 71
- 46. 46NC67-52 List of Exhibits (continued) Exhibit Slide Number
Total Type 2 Diabetes Therapeutics Market: Percent Revenue Forecast
by Region, Global, 20092017 72 Total Type 2 Diabetes Therapeutics
Market: Revenue Forecast by Region, Global, 2009 2017 73 Total
Diabetes Therapeutics Market: Competitive LandscapeInsulin Segment,
Count of Marketed and Pipeline Products by Type and Phase, Global,
2012 75 Total Diabetes Therapeutics Market: Competitive
LandscapeInsulin Segment, Marketed and Pipeline Products by Type,
Global, 2012 76 Total Type 2 Diabetes Therapeutics Market: Insulin
Segment, Marketed Product Synopsis, Global, 2012 77 Total Type 2
Diabetes Therapeutics Market: Insulin Segment Marketed Product
Profiles, Rapid-acting Insulin, Global, 2012 79 Total Type 2
Diabetes Therapeutics Market: Insulin Segment Marketed Product
Profiles, Intermediate-acting/Premix Insulin, Global, 2012 80 Total
Type 2 Diabetes Therapeutics Market: Insulin Segment Marketed
Product Profiles, Basal Insulin, Global, 2012 81 Total Type 2
Diabetes Therapeutics Market: Insulin Segment, Late Stage Product
Synopsis, Global, 2012 82
- 47. 47NC67-52 List of Exhibits (continued) Exhibit Slide Number
Total Type 2 Diabetes Therapeutics Market: Insulin Segment,
MidStage Product Synopsis, Global, 2012 83 Total Type 2 Diabetes
Therapeutics Market: Insulin Segment, Early Stage Product Synopsis,
Global, 2012 84 Total Diabetes Therapeutics Market: Competitive
LandscapeNoninsulin Segment, Count of Marketed and Pipeline
Products by Type and Phase, Global, 2012 86 Total Diabetes
Therapeutics Market: Competitive LandscapeNonInsulin Segment, Late
Stage and Marketed Products by Drug Class, Global, 2012 87 Total
Diabetes Therapeutics Market: Competitive LandscapeNonInsulin
Segment, Number of Early Stage Pipeline Products by Drug Class,
Global, 2012 88 Total Type 2 Diabetes Therapeutics Market:
Non-insulin Segment, Standard of Care Marketed Product Synopsis,
Global, 2012 89 Total Type 2 Diabetes Therapeutics Market:
Non-insulin Segment, Add-on Marketed Product Synopsis, Global, 2012
90 Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment
Marketed Product Profiles, DPP-4s, Global, 2012 94 Total Type 2
Diabetes Therapeutics Market: Non-insulin Segment Marketed Product
Profiles, GLP-1s, Global, 2012 96
- 48. 48NC67-52 List of Exhibits (continued) Exhibit Slide Number
Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment
Marketed Product Profiles, SGLT2s, Global, 2012 98 Total Type 2
Diabetes Therapeutics Market: Insulin Segment, Late Stage Product
Synopsis, Global, 2012 99 Total Type 2 Diabetes Therapeutics
Market: Insulin Segment, MidStage Product Synopsis, Global, 2012
101 Total Type 2 Diabetes Therapeutics Market: Insulin Segment,
EarlyStage Product Synopsis, Global, 2012 105 Total Type 2 Diabetes
Therapeutics Market: Absolute Market Share Trend by Revenue,
Global, 2009 and 2012 110 Total Type 2 Diabetes Therapeutics
Market: Company Market Share Analysis of Top 5 Participants,
Global, 2012 111 Total Type 2 Diabetes Therapeutics Market: SWOT
Analysis, Global, 2012 112 Total Type 2 Diabetes Therapeutics
Market: Timeline of Product Launches, Global, 2010 2018 113 Total
Type 2 Diabetes Therapeutics Market: Patent Expirations, Insulin
Segment, Global, 20002030 114
- 49. 49NC67-52 List of Exhibits (continued) Exhibit Slide Number
Total Type 2 Diabetes Therapeutics Market: Patent Expirations,
Non-insulin Segment, Global, 20002030 115 Total Type 2 Diabetes
Therapeutics Market: Exclusivity Periods of Major Products, Modern
Insulins, Global, 20002030 116 Total Type 2 Diabetes Therapeutics
Market: Exclusivity Periods of Major Products, Non insulin Classes,
Global, 20002030 117 Total Type 2 Diabetes Therapeutics Market:
Cardiovascular Outcomes Trials Timeline, Global, 2012 119 Total
Type 2 Diabetes Therapeutics Market: Comparative Product Profiles
of Promising Late-stage Candidates, Global, 2012 120 Total Type 2
Diabetes Therapeutics Market: Comparative HbA1c Lowering of
Selected Marketed Drugs, Global, 2012 121 Insulin Segment: Percent
Sales Breakdown, Global, 2012 125 Insulin Segment: Market
Engineering Measurements, Global, 2012 126 Insulin Segment: Revenue
Forecast, Global, 20092017 127 Noninsulin Segment: Percent Sales
Breakdown, Global, 2012 130
- 50. 50NC67-52 List of Exhibits (continued) Exhibit Slide Number
Noninsulin Segment: Market Engineering Measurements, Global, 2012
131 Noninsulin Segment: Revenue Forecast, Global, 20092017 132
Insulin Segment: Revenue Forecast, US, 20092017 135 Insulin
Segment: Revenue Forecast by Class, US, 20092017 136 Insulin
Segment: Prevalence and Treated Patient Forecast, US, 20092017 138
Non-insulin Segment: Revenue Forecast, US, 20092017 140 Non-insulin
Segment: Revenue Forecast by Class, US, 20092017 141 Noninsulin
Segment: Evolution of Market Share by Drug Class, US, 2012 and 2017
142 Noninsulin Segment: Prevalence and Treated Patient Forecast,
US, 20092017 143 Total Type 2 Diabetes Therapeutics Market: Pricing
Analysis, US, 2012 145 Diabetes Therapeutics Market: PESTLE
Analysis, US, 2012 147 Diabetes Therapeutics Market: Diabetes
Outlook, The United Kingdom, 2012 and 2030 149 Insulin Segment:
Revenue Forecast, the United Kingdom, 20092017 150
- 51. 51NC67-52 List of Exhibits (continued) Exhibit Slide Number
Non-insulin Segment: Revenue Forecast, the United Kingdom, 20092017
152 Type 2 Diabetes Therapeutics Market: Regulatory Policy
Framework, the United Kingdom, 2012 154 Type 2 Diabetes
Therapeutics Market: Prevalence Forecast, the United Kingdom, 2009
2017 156 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence
and Patient Forecast by Age Groups, The United Kingdom, 2012 and
2017 158 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence
and Patient Forecast by Gender, The United Kingdom, 2012 and 2017
158 Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Germany,
2012 and 2030 161 Insulin Segment: Revenue Forecast, Germany,
20092017 162 Non-insulin Segment: Revenue Forecast, Germany,
20092017 164 Type 2 Diabetes Therapeutics Market: Regulatory Policy
Framework, Germany, 2012 166 Type 2 Diabetes Therapeutics Market:
Prevalence Forecast, Germany, 20092017 168 Type 2 Diabetes
Therapeutics Market: Diabetes Prevalence and Patient Forecast by
Age Groups, Germany, 2012 and 2017 170
- 52. 52NC67-52 List of Exhibits (continued) Exhibit Slide Number
Type 2 Diabetes Therapeutics Market: Diabetes Prevalence and
Patient Forecast by Gender, Germany, 2012 and 2017 170 Type 2
Diabetes Therapeutics Market: Diabetes Outlook , France, 2012 and
2030 173 Insulin Segment: Revenue Forecast, France, 20092017 174
Non-insulin Segment: Revenue Forecast, France, 20092017 176 Type 2
Diabetes Therapeutics Market: Regulatory Policy Framework, France,
2012 178 Type 2 Diabetes Therapeutics Market: Prevalence Forecast,
France, 20092017 180 Type 2 Diabetes Therapeutics Market: Diabetes
Prevalence and Patient Forecast by Age Groups, France, 2012 and
2017 182 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence
and Patient Forecast by Gender, France, 2012 and 2017 182 Type 2
Diabetes Therapeutics Market: Diabetes Outlook, Italy, 2012 and
2030 185 Insulin Segment: Revenue Forecast, Italy, 20092017 186
Non-insulin Segment: Revenue Forecast, Italy, 20092017 188
- 53. 53NC67-52 List of Exhibits (continued) Exhibit Slide Number
Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework,
Italy, 2012 190 Type 2 Diabetes Therapeutics Market: Prevalence
Forecast, Italy, 20092017 192 Type 2 Diabetes Therapeutics Market:
Diabetes Prevalence and Patient Forecast by Age Groups, Italy, 2012
and 201 194 Type 2 Diabetes Therapeutics Market: Diabetes
Prevalence and Patient Forecast by Gender, Italy, 2012 and 2017 194
Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Spain, 2012
and 2030 197 Insulin Segment: Revenue Forecast, Spain, 20092017 198
Non-insulin Segment: Revenue Forecast, Spain, 2009201 200 Type 2
Diabetes Therapeutics Market: Regulatory Policy Framework, Spain,
2012 202 Type 2 Diabetes Therapeutics Market: Prevalence Forecast,
Spain, 20092017 204 Type 2 Diabetes Therapeutics Market: Diabetes
Prevalence and Patient Forecast by Age Group, Spain, 2012 and 2017
206 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence and
Patient Forecast by Gender, Spain, 2012 and 2017 206
- 54. 54NC67-52 List of Exhibits (continued) Exhibit Slide Number
Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Benelux,
2012 and 2030 209 Insulin Segment: Revenue Forecast, Benelux,
20092017 210 Non-insulin Segment: Revenue Forecast, Benelux,
20092017 212 Type 2 Diabetes Therapeutics Market: Regulatory Policy
Framework, Belgium, 2012 214 Type 2 Diabetes Therapeutics Market:
Regulatory Policy Framework, the Netherlands, 2012 215 Type 2
Diabetes Therapeutics Market: Regulatory Policy Framework,
Luxembourg, 2012 216 Type 2 Diabetes Therapeutics Market:
Prevalence Forecast, Benelux, 20092017 220 Type 2 Diabetes
Therapeutics Market: Diabetes Prevalence and Patient Forecast by
Age Groups, Benelux, 2012 and 2017 222 Type 2 Diabetes Therapeutics
Market: Diabetes Prevalence and Patient Forecast by Gender,
Benelux, 2012 and 2017 222 Type 2 Diabetes Therapeutics Market:
Diabetes Outlook, Scandinavia, 2012 and 2030 225 Insulin Segment:
Revenue Forecast, Scandinavia, 20092017 226 Non-insulin Segment:
Revenue Forecast, Scandinavia, 20092017 228
- 55. 55NC67-52 List of Exhibits (continued) Exhibit Slide Number
Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework,
Norway, 2012 230 Type 2 Diabetes Therapeutics Market: Regulatory
Policy Framework, Sweden, 2012 231 Type 2 Diabetes Therapeutics
Market: Regulatory Policy Framework, Denmark, 2012 232 Type 2
Diabetes Therapeutics Market: Regulatory Policy Framework, Finland,
2012 233 Type 2 Diabetes Therapeutics Market: Prevalence Forecast,
Scandinavia, 20092017 238 Type 2 Diabetes Therapeutics Market:
Diabetes Prevalence and Patient Forecast by Age Groups,
Scandinavia, 2012 and 2017 240 Type 2 Diabetes Therapeutics Market:
Diabetes Prevalence and Patient Forecast by Gender, Scandinavia,
2012 and 2017 240 Insulin Segment: Revenue Forecast, China,
20092017 244 Non-insulin Segment: Revenue Forecast, China, 20092017
246 Type 2 Diabetes Therapeutics Market: Pricing Analysis, China,
2012 248 Type 2 Diabetes Therapeutics Market: Prevalence and
Treated Patient Forecast, China, 20092017 249
- 56. 56NC67-52 List of Exhibits (continued) Exhibit Slide Number
Type 2 Diabetes Therapeutics Market: Range of Reported Disease
Prevalence Estimates, China, 2012 250 Type 2 Diabetes Therapeutics
Market: Diabetes Outlook, South Korea, 2012 and 2030 253 Insulin
Segment: Revenue Forecast, South Korea, 20092017 254 Non-insulin
Segment: Revenue Forecast, South Korea, 20092017 256 Type 2
Diabetes Therapeutics Market: Pricing Analysis, South Korea, 2012
258 Type 2 Diabetes Therapeutics Market: Prevalence and Treated
Patient Forecast, South Korea, 20092017 259 Type 2 Diabetes
Therapeutics Market: Diabetes Prevalence by Age Groups, South
Korea, 2012 and 2030 261 Type 2 Diabetes Therapeutics Market:
Diabetes Prevalence by Gender, South Korea, 2012 and 2030 261 Type
2 Diabetes Therapeutics Market: Diabetes Outlook, Malaysia, 2012
and 2030 265 Insulin Segment: Revenue Forecast, Malaysia, 20092017
266 Non-insulin Segment: Revenue Forecast, Malaysia, 20092017
268
- 57. 57NC67-52 List of Exhibits (continued) Exhibit Slide Number
Type 2 Diabetes Market: Pricing Analysis, Malaysia, 2012 270 Type 2
Diabetes Market: Prevalence and Treated Patient Forecast, Malaysia,
20092017 271 Type 2 Diabetes Therapeutics Market: Diabetes
Prevalence by Age Groups, Malaysia, 2012 and 2030 273 Type 2
Diabetes Therapeutics Market: Diabetes Prevalence by Gender,
Malaysia, 2012 and 2030 273 Type 2 Diabetes Therapeutics Market:
Diabetes Outlook, Indonesia, 2012 and 2030 277 Insulin Segment:
Revenue Forecast, Indonesia, 20092017 278 Non-insulin Segment:
Revenue Forecast, Indonesia, 2009-2017 280 Type 2 Diabetes Market:
Prevalence and Treated Patient Forecast, Indonesia, 20092017 283
Type 2 Diabetes Therapeutics Market: Diabetes Prevalence by Age
Groups, Indonesia, 2012 and 2030 285 Type 2 Diabetes Therapeutics
Market: Diabetes Prevalence by Gender, Indonesia, 2012 and 2030 285
Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Vietnam,
2012 and 2030 288
- 58. 58NC67-52 List of Exhibits (continued) Exhibit Slide Number
Insulin Segment: Revenue Forecast, Vietnam, 20092017 289
Non-insulin Segment: Revenue Forecast, Vietnam, 20092017 291 Type 2
Diabetes Therapeutics Market: Pricing Analysis, Vietnam, 2012 294
Type 2 Diabetes Market: Prevalence and Treated Patient Forecast,
Vietnam, 20092017 295 Type 2 Diabetes Therapeutics Market: Diabetes
Prevalence by Age Groups, Vietnam, 2012 and 2030 297 Type 2
Diabetes Therapeutics Market: Diabetes Prevalence by Gender,
Vietnam, 2012 and 2030 297 Insulin Segment: Revenue Forecast,
India, 20092017 300 Non-insulin Segment: Revenue Forecast, India,
20092017 302 Type 2 Diabetes Market: Pricing Analysis, India, 2012
304 Type 2 Diabetes Market: Prevalence and Treated Patient
Forecast, India, 20092017 305 Decision Support Database: Prevalence
of Type 2 Diabetes in Thousands, Global, 2008 2018 331 Decision
Support Database: Prevalence Percent of Type 2 Diabetes, Global,
20082018 334